Considering CCND1 is an important driver of CDK4, CDK4/6 inhibitors as monotherapy or in combination with ICIs may represent a highly promising treatment for patients with melanoma harboring CCND1 amplification (30, 48). Here, CDK4 is linked to melanoma.